

# LITHUANIA

## Recent and planned developments in pharmaceutical policies 2025

### CHANGES IN PRICING

#### Price freezes

To ensure the availability of medicines to patients and considering the budget possibilities and the current macroeconomic conditions, the Ministry of Health assess the appropriateness of freezing reference prices of reimbursed medicines in the last quarter of each year, starting from 2024'th.

#### Pricing monitoring

Ministry of Health approved the list of indicators for monitoring of the impact of the pricing rules of medicines for their availability and budget expenditure. The need for pricing changes will be assessed on the bases of pricing monitoring results (implementation begins in 2025'th)

### CHANGES IN REIMBURSEMENT

#### Co-payment

Fixed maximum co-payment for medicines (5.87 euros) and medical devices (20.33 euros).

#### Patient co-payments covered by State budget when „co-payment basket “amount has been reached:

Patient, who spends more than the three average annual co-payments (i.e. 59.04 euros in 2025'th) during a calendar year when purchasing reimbursable medicines with the lowest co-payment, would be covered for all other reimbursable medicines with the lowest co-payment later in the same year.

	2018	2021	2023	2024
Patient co-payments, million EUR	40,2	17,6	20,8	26,2
Covered patient co-payment by state fund, million EUR	-	15,7	23,9	31,4
Patient co-payments covered by „co-payment basket “, million EUR	-	-	2	3,6

### OTHER CHANGES

#### Medicinal products and pharmaceutical goods data collection

The Government Decision of the Republic of Lithuania approved the statistical research on the sale of medicinal products and pharmaceutical goods in pharmacies and changes in the prices of medicinal products.

The goal is to have accurate data on the structure of the population's expenses for all goods purchased by patients in pharmacies and changes in the prices of medicines. Statistical information will begin to be published on the official statistics portal of the Lithuania in the end of 2025'th.

#### E prescription development


- provides information about shortages of medicine
- integrated information about reimbursement lists of medicines and medical devices
- the possibility of dispensing compound medicines in separate parts of the active substance etc.

### SPECIAL TOPIC:


#### Current advances in HTA

(for EU Member States: Implications from EU-HTA Regulation)

#### Description of the HTA system in Lithuania:



#### Implications of the EU-HTA Regulation:



From January 2025, the decision-makers in the Lithuania system will consider the European Joint Clinical Assessments (JCAs) in their evaluations.